DISEASE & TREATMENT SETTING

Lymphoid Leukemia

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Lymphoid Leukemia

Source population: Not part of this definition
Disease extent: Not part of this definition
Treatment line: Not part of this definition
Stage: Not part of this definition
Resectability: Not part of this definition

Biomarkers, prior therapy and derivation

molecular
prior therapy
derivation status: source-attested
derivation note: Added because the terminology and the registry both attest it: an NCIt neoplasm concept named by 5 acquired study condition(s). It is absent from the NCI treatment-topic directory, which is not an exhaustive cancer inventory.
source wording: Source null

Study evidence for this setting

Find a linked studyHow it was found

6 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

NCT00025662 · Registry condition search · Scope: narrower

Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS

5 outcome links · 1 safety-group records · 0 quality-of-life measures

→

NCT00112593 · Registry condition search · Scope: narrower

Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer

6 outcome links · 1 safety-group records · 0 quality-of-life measures

→

NCT00361140 · Registry condition search · Scope: narrower

Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)

2 outcome links · 3 safety-group records · 0 quality-of-life measures

→

NCT00683046 · Registry condition search · Scope: narrower

T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies

2 outcome links · 1 safety-group records · 0 quality-of-life measures

→

NCT01499147 · Registry condition search · Scope: narrower

Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies

4 outcome links · 3 safety-group records · 0 quality-of-life measures

→

NCT02593123 · Registry condition search · Scope: narrower

Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis

6 outcome links · 2 safety-group records · 0 quality-of-life measures

→

Indication-specific source history

Dated source events, not confirmation of current approval for every use of a drug.

2004-12-28 · Clolar (clofarabine) · accelerated approval

release id: clinical-indications-draft-1
disease state id: ds-lymphoid-leukemia
event id: fda-37008445d0a4c276
event date: 2004-12-28
event kind: accelerated-approval
drug or regimen: Clolar (clofarabine)
source indication text: Treatment of pediatric patients 1 to 21 yrs old with relapsed or refractory acute lymphocytic leukemia (ALL) after at least 2 prior regimens
match phrase: lymphocytic leukemia
match status: candidate
status category: verified_clinical_benefit
has date discrepancy: 0
source collection: fda-status-row
source key: fda-aa-b4cfcec756106ccaedb8
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

2009-10-26 · Arzerra (ofatumumab) · accelerated approval

release id: clinical-indications-draft-1
disease state id: ds-lymphoid-leukemia
event id: fda-327601cff6808bcc
event date: 2009-10-26
event kind: accelerated-approval
drug or regimen: Arzerra (ofatumumab)
source indication text: Chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab
match phrase: lymphocytic leukemia
match status: candidate
status category: verified_clinical_benefit
has date discrepancy: 0
source collection: fda-status-row
source key: fda-aa-4ac21c1dd7ac861dae8d
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

2014-02-12 · Imbruvica (ibrutinib) · accelerated approval

release id: clinical-indications-draft-1
disease state id: ds-lymphoid-leukemia
event id: fda-8660a287a573b22c
event date: 2014-02-12
event kind: accelerated-approval
drug or regimen: Imbruvica (ibrutinib)
source indication text: Chronic lymphocytic leukemia after at least one prior therapy
match phrase: lymphocytic leukemia
match status: candidate
status category: verified_clinical_benefit
has date discrepancy: 0
source collection: fda-status-row
source key: fda-aa-6231c98cea2f27ce3f56
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

2014-04-17 · Arzerra (ofatumumab) · traditional approval

release id: clinical-indications-draft-1
disease state id: ds-lymphoid-leukemia
event id: fda-a8a643e378b874bb
event date: 2014-04-17
event kind: traditional-approval
drug or regimen: Arzerra (ofatumumab)
source indication text: Chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab
match phrase: lymphocytic leukemia
match status: candidate
status category: verified_clinical_benefit
has date discrepancy: 0
source collection: fda-status-row
source key: fda-aa-4ac21c1dd7ac861dae8d
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

2014-07-28 · Imbruvica (ibrutinib) · traditional approval

release id: clinical-indications-draft-1
disease state id: ds-lymphoid-leukemia
event id: fda-67d4fa20db32c9fb
event date: 2014-07-28
event kind: traditional-approval
drug or regimen: Imbruvica (ibrutinib)
source indication text: Chronic lymphocytic leukemia after at least one prior therapy
match phrase: lymphocytic leukemia
match status: candidate
status category: verified_clinical_benefit
has date discrepancy: 0
source collection: fda-status-row
source key: fda-aa-6231c98cea2f27ce3f56
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

2016-04-11 · Venclexta (venetoclax) · accelerated approval

release id: clinical-indications-draft-1
disease state id: ds-lymphoid-leukemia
event id: fda-ba1bb11d63eb5f2d
event date: 2016-04-11
event kind: accelerated-approval
drug or regimen: Venclexta (venetoclax)
source indication text: Chronic lymphocytic leukemia with 17P deletion as detected by an FDA-approved test, after at least one prior therapy
match phrase: lymphocytic leukemia
match status: candidate
status category: verified_clinical_benefit
has date discrepancy: 0
source collection: fda-status-row
source key: fda-aa-53da3fe02d37c0867b7e
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

2018-06-08 · Venclexta (venetoclax) · traditional approval

release id: clinical-indications-draft-1
disease state id: ds-lymphoid-leukemia
event id: fda-5b602f3762f8a6f7
event date: 2018-06-08
event kind: traditional-approval
drug or regimen: Venclexta (venetoclax)
source indication text: Chronic lymphocytic leukemia with 17P deletion as detected by an FDA-approved test, after at least one prior therapy
match phrase: lymphocytic leukemia
match status: candidate
status category: verified_clinical_benefit
has date discrepancy: 0
source collection: fda-status-row
source key: fda-aa-53da3fe02d37c0867b7e
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

2022-07-18 · Clolar (clofarabine) · traditional approval

release id: clinical-indications-draft-1
disease state id: ds-lymphoid-leukemia
event id: fda-6d945af322317a63
event date: 2022-07-18
event kind: traditional-approval
drug or regimen: Clolar (clofarabine)
source indication text: Treatment of pediatric patients 1 to 21 yrs old with relapsed or refractory acute lymphocytic leukemia (ALL) after at least 2 prior regimens
match phrase: lymphocytic leukemia
match status: candidate
status category: verified_clinical_benefit
has date discrepancy: 0
source collection: fda-status-row
source key: fda-aa-b4cfcec756106ccaedb8
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

2023-12-01 · Jayprica (pirtobrutinib) · accelerated approval

release id: clinical-indications-draft-1
disease state id: ds-lymphoid-leukemia
event id: fda-d5befa963912c831
event date: 2023-12-01
event kind: accelerated-approval
drug or regimen: Jayprica (pirtobrutinib)
source indication text: Adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor
match phrase: lymphocytic leukemia
match status: candidate
status category: verified_clinical_benefit
has date discrepancy: 0
source collection: fda-status-row
source key: fda-aa-f46040f9a05ea161be30
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

2024-03-21 · Breyanzi (lisocabtagene maraleucel) · accelerated approval

release id: clinical-indications-draft-1
disease state id: ds-lymphoid-leukemia
event id: fda-5ac677ed2d82e228
event date: 2024-03-21
event kind: accelerated-approval
drug or regimen: Breyanzi (lisocabtagene maraleucel)
source indication text: Adult patients with relapsed/ refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in patients who have received at least two prior lines of therapy including a Bruton’s tyrosine kinase (BTK) inhibitor and a B-cell lymphoma-2 (BCL-2) inhibitor
match phrase: lymphocytic leukemia
match status: candidate
status category: ongoing
has date discrepancy: 0
source collection: fda-status-row
source key: fda-aa-75ffcc7a7a2999eed44d
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

2025-12-02 · Jayprica (pirtobrutinib) · traditional approval

release id: clinical-indications-draft-1
disease state id: ds-lymphoid-leukemia
event id: fda-085a9660609cb09b
event date: 2025-12-02
event kind: traditional-approval
drug or regimen: Jayprica (pirtobrutinib)
source indication text: Adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor
match phrase: lymphocytic leukemia
match status: candidate
status category: verified_clinical_benefit
has date discrepancy: 0
source collection: fda-status-row
source key: fda-aa-f46040f9a05ea161be30
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

2025-12-03 · pirtobrutinib · approval notification

release id: clinical-indications-draft-1
disease state id: ds-lymphoid-leukemia
event id: notice-543bc2f69a2198c4
event date: 2025-12-03
event kind: approval-notification
drug or regimen: pirtobrutinib
source indication text: FDA approved pirtobrutinib for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who have previously been treated with a covalent BTK inhibitor. In 2023, FDA granted accelerated approval to pirtobrutinib for adults with CLL/SLL who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
match phrase: lymphocytic leukemia
match status: candidate
status category: traditional
has date discrepancy: 0
source collection: fda-approval-notice
source key: fda-a90b83cba53cf44c
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-traditional-approval-pirtobrutinib-chronic-lymphocytic-leukemia-and-small-lymphocytic
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

2026-02-19 · acalabrutinib with venetoclax · approval notification

release id: clinical-indications-draft-1
disease state id: ds-lymphoid-leukemia
event id: notice-de319acd23c4ed86
event date: 2026-02-19
event kind: approval-notification
drug or regimen: acalabrutinib with venetoclax
source indication text: FDA approved acalabrutinib tablets and capsules in combination with venetoclax for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma .
match phrase: lymphocytic leukemia
match status: candidate
status category: Source null
has date discrepancy: 0
source collection: fda-approval-notice
source key: fda-2484637c7ad88112
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-acalabrutinib-venetoclax-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

Source relationships and population-mapping limitations

bindings

release id
clinical-indications-draft-1
disease state id
ds-lymphoid-leukemia
binding id
ncit-C7539
source collection
ncit-concept
source key
C7539
source excerpt
Source null
match status
exact
match note
Source null
recorded at
2026-09-10T00:00:00Z

mappings

Download this complete draft source relationship record →

Preserved source evidence · Not medical advice